Literature DB >> 2822333

Relationships between CSF drug concentrations, receptor binding characteristics, and pharmacokinetic and pharmacodynamic properties of selected 1,4-substituted benzodiazepines.

W A Colburn1, M L Jack.   

Abstract

Pharmacokinetic profiles of the 1,4-substituted benzodiazepines are defined by their absorption, distribution, metabolism, and excretion characteristics. An ability to cross the blood-brain barrier and the onset of pharmacological activity have been associated with the physiochemical properties of the benzodiazepines. In addition, drug concentrations in the CSF correlate with the unbound drug concentrations in blood or plasma. Duration of pharmacological activity of the benzodiazepines in humans is associated with the affinity of these compounds for the benzodiazepine receptors in human brain. Therefore, benzodiazepines with high affinity for the benzodiazepine receptor sites in human brain tend to exhibit prolonged half-lives of elimination from the CSF which correlate with the prolonged duration of clinical and pharmacological effects and lower therapeutic doses of these drugs in vivo.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2822333     DOI: 10.2165/00003088-198713030-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  44 in total

1.  The importance of dissociaton constant and lipid-solubility in influencing the passage of drugs into the cerebrospinal fluid.

Authors:  B B BRODIE; H KURZ; L S SCHANKER
Journal:  J Pharmacol Exp Ther       Date:  1960-09       Impact factor: 4.030

2.  Pharmacokinetics of the anticonvulsant drug clonazepam evaluated from single oral and intravenous doses and by repeated oral administration.

Authors:  A Berlin; H Dahlström
Journal:  Eur J Clin Pharmacol       Date:  1975-12-19       Impact factor: 2.953

3.  Residual effects and skills related to driving after a single oral administration of diazepam, medazepam or lorazepam.

Authors:  K Seppälä; K Korttila; S Häkkinen; M Linnoila
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

4.  Cerebrospinal fluid concentrations and serum protein binding of lorazepam and its conjugate.

Authors:  L Aaltonen; J Kanto; M Salo
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1980-02

5.  Data compilation. Benzodiazepine compounds. A listing of pharmacokinetic data, plasma protein binding and ionization constants from current literature.

Authors:  R Whelpton
Journal:  Biopharm Drug Dispos       Date:  1979 Jul-Sep       Impact factor: 1.627

6.  CSF penetration and pharmacokinetics of midazolam.

Authors:  S Sjövall; J Kanto; J J Himberg; M Hovi-Viander; M Salo
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 7.  Pharmacology of midazolam.

Authors:  L Pieri; R Schaffner; R Scherschlicht; P Polc; J Sepinwall; A Davidson; H Möhler; R Cumin; M Da Prada; W P Burkard; H H Keller; R K Müller; M Gerold; M Pieri; L Cook; W Haefely
Journal:  Arzneimittelforschung       Date:  1981

Review 8.  Clinical pharmacokinetics of diazepam.

Authors:  M Mandelli; G Tognoni; S Garattini
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

9.  Persistent behavioural and electroencephalographic changes after single doses of nitrazepam and amylobarbitone sodium.

Authors:  A Malpas; A J Rowan; C R Boyce; D F Scott
Journal:  Br Med J       Date:  1970-06-27

10.  Entry of diazepam and its major matabolite into cerebrospinal fluid.

Authors:  D J Greenblatt; H R Ochs; B L Lloyd
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

View more
  12 in total

Review 1.  Pharmacokinetic optimisation of antiemetic therapy.

Authors:  M Campbell; D N Bateman
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

2.  Relationship between drug plasma concentrations and psychomotor performance after single doses of ethanol and benzodiazepines.

Authors:  J Ingum; R Bjørklund; A Bjørneboe; A S Christophersen; E Dahlin; J Mørland
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease.

Authors:  M Contin; R Riva; P Martinelli; F Albani; A Baruzzi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  The use of kinetic-dynamic interactions in the evaluation of drugs.

Authors:  D B Campbell
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 5.  Current models in pharmacokinetics: applications in veterinary pharmacology.

Authors:  L D Kinabo; Q A McKellar
Journal:  Vet Res Commun       Date:  1989       Impact factor: 2.459

6.  Pharmacokinetic/pharmacodynamic modeling: what it is!

Authors:  W A Colburn
Journal:  J Pharmacokinet Biopharm       Date:  1987-10

Review 7.  Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem.

Authors:  G Chouinard; K Lefko-Singh; E Teboul
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

8.  Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. II. Triazolam.

Authors:  S K Gupta; E H Ellinwood; A M Nikaido; D G Heatherly
Journal:  Pharm Res       Date:  1990-06       Impact factor: 4.200

9.  Peripheral benzodiazepine receptors in platelets of epileptic patients.

Authors:  J G Larkin; P J McKee; G G Thompson; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1993-07       Impact factor: 4.335

10.  Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat.

Authors:  L E van Beijsterveldt; R J Geerts; J E Leysen; A A Megens; H M Van den Eynde; W E Meuldermans; J J Heykants
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.